Benign versus secondary-progressive multiple sclerosis: The potential role of proton MR spectroscopy in defining the nature of disability

American Journal of Neuroradiology

Volumn 19, Issue 2, 1998, Pages 223-229

  Falini, A ^a,b   Calabrese, G ^a   Filippi, M ^a   Origgi, D ^a   Lipari, S ^a   Colombo, B ^a   Comi, G ^a   Scotti, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; INOSITOL; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; ASPARTIC ACID; BRAIN; CHOLINE; CREATINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INOSITOL; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION;

EID: 0032470810     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Sadiq SA, Miller JR. Multiple sclerosis, Devic syndrome and Balo disease. In: Rowland LP, ed. Merrit Talbook of Neurology. 9th ed. Baltimore, Md: Williams & Wilkins; 1995:804-826
2. Adams RD, Victor M. Multiple Sclerosis and allied demyelinative diseases. In: Adams RD, Victor M, eds. Principles of Neurology. 5th ed. New York, NY: McGraw-Hill; 1993:776-798
3. Marburg O. Die sogenante "akute multiple sklerosis" (encephalomyelitis periapicalis scleroticans). J Psychiatr Neurol 1906;27:211-312
4. Johnson MD, Lavin P, Whetsell WO Jr. Fulminant monophasic multiple sclerosis, Marburg's type. J Neurol Neurosurg Psychiatry 1990;53:918-921
5. Niebler G, Harris T, Davis T, Ross K. Fulminant multiple sclerosis. AJNR Am J Neuroradiol 1992;13:1547-1551
6. Lublin FD, Reigold SC, for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911
7. Koopmans RA, Li DKB, Grochowsky E, Cutler PJ, Paty DW. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol 1989;25:74-81
8. Filippi M, Campi A, Mammi S, et al. Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis: a follow up study. J Neurol Neurosurg Psychiatry 1995;58:31-37
9. Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald WI. Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994;57:1070-1072
10. Horsfield MA, Lai M, Webb SL, et al. Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. Magn Reson Med 1996;36:393-400
11. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14:154-159
12. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990;40: 1764-1769
13. Larsson HB, Christiansen P, Jensen M, et al. Localized in vivo proton spectrosocpy in the brain of patients with multiple sclerosis. Magn Reson Med 1991;22:23-31
14. Matthews PM, Francis MD, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology 1991;41:1251-1256
15. Miller DH, Austin SJ, Connelly A, Youl BD, Gadian DG, McDonald WI. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet 1991;337:58-59
16. Richards TL. Proton MR spectrosocpy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy. AJR Am J Roentgenol 1991;157:1073-1078
17. Van Hecke P, Marchal G, Johannik K, et al. Human brain proton localized NMR spectroscopy in multiple sclerosis. Magn Reson Med 1991;18:199-206
18. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel J. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992;31: 235-241
19. Bruhn H, Frahm J, Merboldt KD, et al. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 1992; 32:140-150
20. Grossman RI, Lenkiski RE, Ramer KN, Gonzalez-Scarano F, Cohen JA. MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 1992;13:1535-1543
21. Davie CA, Hawkins CP, Barker CJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58
22. Hiehle JF, Lenkinski RE, Grossman RI, et al. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn Reson Med 1994;32:285-293
23. Roser W, Hagberg G, Mader I, et al. Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter. Magn Reson Med 1995;33:811-817
24. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
25. Kurtze JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33: 1442-1452
26. Haase A, Frahm J, Haenicke W, Matthei D. 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol 1985;30:341-344
27. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitling multiple sclerosis. Neurology 1993; 43:655-661
28. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
29. The IFNB Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized, controlled trial. Neurology 1995;45:1277-1285
30. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688
31. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16
32. Nadler JV, Cooper JR. N-acetyl-L-aspartic acid content of human neural tumors and bovine peripheral nervous tissue. J Neurochem 1972;19:313-319
33. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37-45
34. Hanstock CC, Rothman DL, Prichard JW, Jue T, Shulman RG. Spatially localized 1H NMR spectra of metabolite in the human brain. Proc Natl Acad Sci 1988;85:1821-1825
35. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold LA. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901-909
36. Tzika AA, Ball WS, Vigneron DB, Scott Dunn R, Kirks DR. Clinical proton MR spectroscopy of neurodegenerative disease in childhood. AJNR Am J Neuroradiol 1993;4:1267-1281
37. Ross BD. Biochemical consideration in 1H spectroscopy: glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed 1991;4:59-62
38. Murphy S. Astrocytes: Pharmacology and Function. San Diego, Calif: Academic Press; 1993
39. Lien HH, Shapiro JL, Chan L. Effects of hypernatremia on organic brain osmolytes. J Clin Invest 1990;85:1427-1435
40. Graf J, Guggino WB, Turnheim K. Volume regulation in transporting epithelia. In: Lang F, Haussinger D, eds. Interactions in Cell Volume and Cell Function. Heidelberg, Germany: Springer-Verlag; 1993:67-117
41. Kimelberg HK, O'Connor ER, Kettenmann H. Effect of swelling on glial cell function. In: Lang F, Haussinger D, eds. Interactions in Cell Volume and Cell Function. Heidelberg, Germany: Springer-Verlag; 1993;158-186
42. Laubenberger J, Haussinger D, Bayer S, et al. HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times. Radiology 1996;199:805-810
43. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neurons cells. Dev Neurosci 1993;15:289-298
44. May GL, Wright LC, Holmes KT, Williams PG, Smith ICP, Wright PE. Assignment of methylene proton resonances in NMR spectra of embryonic and transformed cells to plasma membrane triglyceride. J Biol Chem 1986;261:3048-3053
45. Feinstein A, Kartsounis LD, Miller DH, Youl BD, Ron MA. Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry 1992;55:869-876
46. Millefiorini E, Padovani A, Pozzilli C, et al. Depression in the early phase of MS: influence of functional disability, cognitive impairment and brain abnormalities. Acta Neurol Scand 1992;86:354-358
47. Mèoller A, Wiedemann G, Rohde U, Backmund H, Sonntag A. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand 1994;89:117-121
48. Comi G, Filippi M, Martinelli V, et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 1995;132:222-227